A5063219804- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Esophageal and GI Pathology
- Cancer Immunotherapy and Biomarkers
- Esophageal Cancer Research and Treatment
- Immunotherapy and Immune Responses
- Genetic factors in colorectal cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Mass Spectrometry Techniques and Applications
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
- Helicobacter pylori-related gastroenterology studies
- Immune cells in cancer
- Monoclonal and Polyclonal Antibodies Research
- Cancer Cells and Metastasis
- Metastasis and carcinoma case studies
- HER2/EGFR in Cancer Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Virus-based gene therapy research
- Cancer Genomics and Diagnostics
- Ferroptosis and cancer prognosis
Hôpital de la Timone
2020-2024
Aix-Marseille Université
2021-2023
Centre de Recherche en Cancérologie de Marseille
2022-2023
Inserm
2022-2023
Centre National de la Recherche Scientifique
2022-2023
Assistance Publique Hôpitaux de Marseille
2021-2022
Many cancers cannot be detected early due to lack of effective disease biomarkers, leading poor prognosis. We applied an existing biophysical technology nanoDSF in a novel way answer this unmet biomedical need. developed breakthrough digital biomarker method for cancer detection based on AI-classification plasma denaturation profiles (PDPs) obtained by technology. PDPs from 300 samples patients with melanoma, brain, digestive or lung were automatically distinguished healthy accuracy 94%....
Hepatocellular carcinoma (HCC) is a frequent and deadly cancer in need of new treatments. Immunotherapy has shown promising results several solid tumors. The TIGIT/DNAM-1 axis gathers targets for immune checkpoint inhibitors (ICIs). Here, we aimed at highlighting the potential this as therapeutic option HCC. For this, built large transcriptomic database 683 HCC samples, clinically annotated, 319 normal liver tissues. We interrogated expression each member tested their prognostic value...
Several studies have reported the impact of single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor (VEGF) pathway genes on efficacy bevacizumab metastatic colorectal cancer (mCRC), but results are still inconsistent. The PRODIGE 9 phase III study compared maintenance versus observation alone after induction chemotherapy with FOLFIRI plus bevacizumab.We evaluated SNPs VEGF-A, VEGF receptors (VEGFR-1, VEGFR-2), and hypoxia inducible factor-1α (HIF-1α) tumor control...
Radiotherapy combined with fluorouracil (5FU) and cisplatin for locally advanced esophageal cancer is associated a 20-25% pathologic complete response (pCR) rate. Cetuximab increases the efficacy of radiotherapy in patients head neck carcinomas. The aim this phase I/II trial was to determine optimal doses pCR rate chemoradiotherapy (C-RT) plus cetuximab.
Introduction: Tumor-based molecular profiling has increased in the area of precision medicine. Their routine use is still limited by accessibility, cost and availability tumor material. Materials Methods: We retrospectively analysed treatment received survival data patients with digestive cancer who high-throughput sequencing (NGS) analyses at diagnosis. The primary objective this single-center study was to compare overall were treated molecularly matched therapy standard therapy. Median...